Revvity (RVTY) received a positive response from investors reflecting a 53% gain in the last five years. Based on the insights from 8 financial analysts, the target price of the stock has been raised to $135.00. However, RVTY's share saw a 2.8% decrease, despite the demand for diagnostic products boosting their profit and sales.
The Q2 earnings beat expectations and gained an increased rating to Overweight at Barclays. Confirming the strong earnings, Gateway Investment Advisors acquired 34,428 shares of Revvity. However, insider selling has been spotted. Meanwhile, Barclays upgraded Revvity (NYSE:RVTY) to Overweight, with the stock showing considerable potential but it's cautioned that buying in cheap might be difficult.
On other developments, PerkinElmer, a life sciences business, has been rebranded as Revvity. Furthermore, there's a raised stake from Handelsbanken Fonder AB in Revvity.
Revvity RVTY News Analytics from Thu, 08 Sep 2011 07:00:00 GMT to Sat, 19 Oct 2024 05:44:58 GMT - Rating 8 - Innovation -5 - Information 6 - Rumor -4
